1.Research progress and current status of immunotherapy and ablation therapy in hepatocellular carcinoma
Qian MA ; Lele CHANG ; Ji TAO
Cancer Research and Clinic 2023;35(12):947-950
As solid tumor therapy enters the immunological era, hepatocellular carcinoma immunotherapy starts in advanced second-line, from second-line to first-line, from single agent to combination, and from late stage to early stage. Radiofrequency ablation and microwave ablation have become first-line therapies for local ablation of early hepatocellular carcinoma, and emerging ablation techniques are also being developed in clinical trials and/or cell/animal studies. In the exploration of treatment regimens of hepatocellular carcinoma, the limitation of single therapy has become increasingly obvious, and the exploration of combination therapy has begun. This article reviews the research progress of immunotherapy and ablation therapy in hepatocellular carcinoma, aiming to provide new directions and insights for clinical treatment of hepatocellular carcinoma.
2.Clinical and genetic analysis of a Chinese pedigree affected with Dyggve-Melchior-Clausen syndrome due to a novel frameshift variant of DYM gene.
Lele KUANG ; Rui PENG ; Bin LIU ; Di XI ; Qiurong CHANG ; Yuping GAO
Chinese Journal of Medical Genetics 2022;39(4):370-373
OBJECTIVE:
To explore the genetic basis of a Chinese pedigree affected with Dyggve-Melchior-Clausen syndrome.
METHODS:
Whole exome sequencing and Sanger sequencing were carried out to detect potential pathogenic variants associated with the syndrome. The function of candidate variant was verified by Western blotting.
RESULTS:
A novel homozygous variant, c.1222delG of the DYM gene was detected in the two affected siblings, for which both parents were heterozygous carriers. The variant has caused replacement of Asp by Met at amino acid 408 and generate a premature stop codon p.Asp408Metfs*10. Western blotting confirmed that the variant can result in degradation of the mutant DYM protein, suggesting that it is a loss of function variant.
CONCLUSION
The homozygous c.1222delG frameshift variant of the DYM probably underlay the Dyggve-Melchior-Clausen syndrome in the two affected siblings. Above findings has enabled clinical diagnosis and genetic counseling for the family.
China
;
Dwarfism/genetics*
;
Humans
;
Intellectual Disability
;
Osteochondrodysplasias/genetics*
;
Pedigree
3.Singapore rhabdomyosarcoma (RMS) experience: shall we change our practice?
Lele AUNG ; Tin Aung SOE ; Kenneth Te CHANG ; Thuan Chong QUAH
Annals of the Academy of Medicine, Singapore 2014;43(2):86-95
INTRODUCTIONAlthough rhabdomyosarcoma (RMS) constitutes nearly 4% of all children diagnosed with cancer in the ethnically diverse small island city of Singapore, it is unknown how children with RMS fare.
MATERIALS AND METHODSThis study investigated 50 children with RMS from April 1993 to December 2010 from KK Women's and Children's Hospital (KKH) and National University Hospital (NUH). They were treated either as per Intergroup Rhabdomyosarcoma Study Group (IRSG) or Société Internationale Pediatrique D'Oncologie (SIOP) regimens.
RESULTSMedian age of diagnosis was 5.1 years (range, 0.1 to 17.3 years) with a median follow-up of 3.3 years (range, 0.4 to 15.6 years). According to IRSG classifi cation, 18 (36%) were staged as low-risk (LR); 19 (38%) were intermediate-risk (IR), 12 (24%) were high-risk (HR) and it was unknown in 1 patient. Twenty-nine (58%) were of embryonal subtype, 17 (34%) were alveolar and subclassification was not available in 4. The primary sites of tumour were: head and neck region (n = 22); genitourinary (n = 19); extremity (n = 10); and abdomen/retroperitoneal (n = 5). At the time of analysis, 80% were alive with no evidence of disease, 9 were dead of disease, and 2 were alive with disease. By disease risk group, the 5-year event-free survival (EFS) for LR group disease was 81.3% (95% CI, 62.0 to 100.0), IR group was 61.4% (95% CI, 32.3 to 90.4) and HR group was 25.0% (95% CI, 0.0 to 49.5) respectively (P <0.001). The 5-year EFS for risk by chemotherapy received as per SIOP vs per IRSG revealed: LR 83.3% vs 75.0% (P = 0.787); IR 83.3% vs 43.8% (P = 0.351); HR 0.0% vs 42.9% (P = 0.336) respectively. Of 15 relapses (HR, n = 7), at median of 2 years, 4 of 6 patients treated as per SIOP regimen were dead of disease and 3 of 8 treated as per IRSG were alive.
CONCLUSIONRadiation therapy (RT) can be avoided in LR classification although those in higher risk classification need RT to local and distant metastatic disease. The outcome of children with RMS in Singapore can be further improved by coming together as a cooperative group to provide the best total care. Improved communication, multidisciplinary team collaboration, standardisation of protocols and rigorous data collection are keys.
Adolescent ; Child ; Child, Preschool ; Humans ; Infant ; Neoplasm Recurrence, Local ; therapy ; Practice Patterns, Physicians' ; Retrospective Studies ; Rhabdomyosarcoma ; therapy ; Singapore

Result Analysis
Print
Save
E-mail